Is SYNI stock a buy after the collapse?

SYNI stock is a high-risk speculative trade. A tactical oversold bounce can be considered only after volume-backed reversal and clear catalysts. Keep positions small and use strict stops because dilution and delisting are real risks.

What drives upside for SYNI stock?

Upside drivers are clinical trial progress for ALT-2074 or alagebrium, licensing deals, or successful refinancing. Given current liquidity, any tangible funding news could trigger sharp moves in SYNI stock.

How should I size a trade in SYNI stock?

Size any SYNI stock position as a small percentage of speculative capital only. Use staged buys, clear stop losses under the intraday low, and avoid letting a single microcap position exceed a predefined risk limit.

What valuation metrics matter for SYNI stock?

Traditional PE is non-meaningful for SYNI stock due to negative earnings (EPS **-7.66**). Focus instead on cash runway, clinical milestone probability, and dilution risk when assessing valuation.

US Stocks

SYNI Synvista Therapeutics (PNK) at $0.00 on 18 Feb 2026: Oversold bounce may offer tactical entry

ByHuzaifa Zahoor February 18, 2026February 18, 2026

SYNI stock is trading effectively at $0.00 (quoted at $0.000001) on 18 Feb 2026 during U.S. market hours, following a collapse from a $0.08 previous close. This extreme move leaves short-term technical indicators at depressed levels and creates an oversold bounce setup that traders may consider for a tactical entry. We review fundamentals, volume, liquidity and clinical catalysts to frame a disciplined oversold-bounce approach for Synvista Therapeutics, Inc. (SYNI) on the PNK exchange in the United States, using Meyka AI real-time analysis and market-grade metrics.